Your browser is no longer supported. Please, upgrade your browser.
Salarius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own0.10% Shs Outstand44.76M Perf Week8.82%
Market Cap46.12M Forward P/E- EPS next Y-0.35 Insider Trans36.01% Shs Float44.10M Perf Month18.09%
Income-8.80M PEG- EPS next Q-0.08 Inst Own27.60% Short Float3.16% Perf Quarter2.78%
Sales4.70M P/S9.81 EPS this Y76.60% Inst Trans-31.99% Short Ratio1.00 Perf Half Y-19.57%
Book/sh1.02 P/B1.09 EPS next Y-20.70% ROA-24.10% Target Price- Perf Year38.06%
Cash/sh0.80 P/C1.39 EPS next 5Y- ROE-25.60% 52W Range0.63 - 3.50 Perf YTD21.98%
Dividend- P/FCF- EPS past 5Y60.50% ROI-34.30% 52W High-68.29% Beta1.57
Dividend %- Quick Ratio24.70 Sales past 5Y- Gross Margin- 52W Low75.63% ATR0.07
Employees9 Current Ratio24.70 Sales Q/Q-50.00% Oper. Margin- RSI (14)60.78 Volatility6.86% 6.30%
OptionableNo Debt/Eq0.00 EPS Q/Q46.30% Profit Margin- Rel Volume1.30 Prev Close1.05
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume1.39M Price1.11
Recom1.70 SMA205.97% SMA5018.26% SMA200-10.01% Volume1,826,931 Change5.71%
Apr-27-20Initiated Ladenburg Thalmann Buy $3.80
Sep-22-21 07:33AM  
Sep-20-21 08:35AM  
Sep-15-21 08:03AM  
Sep-10-21 08:35AM  
Sep-08-21 08:13AM  
Aug-12-21 02:00PM  
Aug-10-21 06:16AM  
Aug-05-21 07:32AM  
Jul-29-21 07:33AM  
Jul-14-21 08:05AM  
Jul-13-21 07:33AM  
Jul-09-21 07:33AM  
Jun-17-21 08:03AM  
Jun-15-21 07:30AM  
Jun-10-21 01:30PM  
Jun-07-21 07:35AM  
May-19-21 05:01PM  
May-12-21 04:05PM  
May-05-21 07:05AM  
Apr-29-21 07:30AM  
Apr-19-21 07:30AM  
Mar-18-21 04:05PM  
Mar-11-21 04:15PM  
Mar-08-21 04:05PM  
Mar-04-21 08:30AM  
Mar-03-21 04:05PM  
Feb-24-21 07:00AM  
Feb-22-21 07:30AM  
Feb-17-21 09:00AM  
Feb-16-21 07:30AM  
Feb-10-21 06:21AM  
Jan-21-21 08:05AM  
Jan-15-21 07:30AM  
Jan-13-21 07:30AM  
Dec-22-20 07:30AM  
Dec-11-20 11:32AM  
Dec-10-20 09:28AM  
Nov-17-20 07:30AM  
Nov-11-20 04:05PM  
Nov-04-20 07:30AM  
Oct-13-20 07:30AM  
Sep-21-20 08:35AM  
Sep-14-20 08:35AM  
Sep-10-20 07:30AM  
Aug-27-20 10:00AM  
Aug-12-20 04:05PM  
Aug-06-20 02:01PM  
Aug-05-20 09:30AM  
Aug-03-20 04:05PM  
Jul-30-20 09:22AM  
Jul-29-20 04:15PM  
Jul-28-20 08:00AM  
Jul-23-20 08:00AM  
Jun-02-20 09:00AM  
May-27-20 08:00AM  
May-22-20 09:24AM  
May-14-20 04:05PM  
May-07-20 04:05PM  
Apr-29-20 07:30AM  
Apr-22-20 08:00AM  
Apr-13-20 03:15PM  
Mar-23-20 04:18PM  
Mar-04-20 08:00AM  
Mar-02-20 08:00AM  
Feb-11-20 04:05PM  
Feb-10-20 08:00AM  
Feb-07-20 08:31AM  
Feb-05-20 08:00AM  
Feb-04-20 08:00AM  
Dec-19-19 08:00AM  
Dec-17-19 08:00AM  
Dec-16-19 08:00AM  
Dec-12-19 08:00AM  
Nov-13-19 08:00AM  
Oct-28-19 03:08PM  
Oct-15-19 10:47AM  
Oct-14-19 08:00AM  
Oct-08-19 08:00AM  
Sep-24-19 08:00AM  
Sep-13-19 08:00AM  
Sep-12-19 08:00AM  
Aug-26-19 07:00AM  
Aug-12-19 08:00AM  
Jul-30-19 03:29PM  
Jul-29-19 09:02AM  
Jul-24-19 04:05PM  
Jul-22-19 08:05AM  
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arthur David J.Chief Executive OfficerAug 17Buy0.904,0003,582102,247Aug 17 04:08 PM
HANISH ARNOLD CDirectorAug 10Buy0.887,0006,16718,350Aug 11 04:08 PM